Fundraising Fox

GenrAb

Dallas, US · Founded 2022 · Delaware corporation

GenrAb develops neuroprotective therapies derived from the human immune system to treat neurological diseases including ALS, Parkinson's, Alzheimer's, and Multiple Sclerosis. The company addresses unmet needs in neurodegeneration treatment by harnessing immunological pathways to prevent disease progression.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Founders & leadership

GenrAb was founded in 2022 by Dr. Ben Greenberg and Dr. Nancy Monson.

DB
Dr. Ben GreenbergCEO/CMO
DN
Dr. Nancy MonsonCSO
RV
Richard VincentExecutive
LT
Larry TiffanyExecutive

Board

NW
Neil WarmaBoard director
DK
Doug KerrBoard director

Funding

SEC filings, press & company announcements

$4.6M disclosed across 1 of 3 rounds · 2022–2025

▶$4.6MraisedApr 2025 · 48 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Neil WarmaDirector
  • Richard VincentExecutive Officer
  • Nancy MonsonExecutive Officer, Promoter
  • Doug KerrDirector
  • Larry TiffanyExecutive Officer, Director
  • Benjamin GreenbergExecutive Officer
Offering amount
$5.9M
Amount sold
$4.6M
Sales commissions
$80K
Placement agents
Salem Partners LLC
First sale
Dec 2022
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Thumbnail for Seragon Pharmaceuticals3 shared keywordsGenentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.

Companies competing with GenrAb for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

UT Southwestern Spinout Emerges From Stealth With $5.6M to Push 'First in Class' Neuroprotective Therapy Into the Clinic » Dallas Innovatesdallasinnovates.com · Apr 2025GenrAb Secures $5.6 Million Funding for Neuroprotective Innovations - Investors Hangoutinvestorshangout.com · Apr 2025GenrAb Closes $5.6M Seed Financingfinsmes.com · Apr 2025GenrAb Completes $5.6 Million Financing to Accelerate Development of its Lead Antibody Therapy (TGM-010) and Expand Pipeline of Neuroprotective Candidatesprnewswire.com · Apr 2025

Frequently asked questions

What does GenrAb do?
GenrAb develops neuroprotective therapies derived from the human immune system to treat neurological diseases including ALS, Parkinson's, Alzheimer's, and Multiple Sclerosis. The company addresses unmet needs in neurodegeneration treatment by harnessing immunological pathways to prevent disease progression.
Who founded GenrAb?
GenrAb was founded by Dr. Ben Greenberg, Dr. Nancy Monson in 2022.
How much funding has GenrAb raised?
GenrAb has disclosed $4.6M raised across 1 of its 3 known rounds.
Where is GenrAb headquartered?
GenrAb is headquartered in Dallas, US.